Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) EBITDA (2020 - 2025)

Maxcyte (MXCT) has disclosed EBITDA for 6 consecutive years, with $32.4 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 5.15% to $32.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$6.2 million through Dec 2025, down 14.72% year-over-year, with the annual reading at -$5.1 million for FY2025, 19.14% down from the prior year.
  • EBITDA for Q4 2025 was $32.4 million at Maxcyte, up from -$13.1 million in the prior quarter.
  • The five-year high for EBITDA was $32.4 million in Q4 2025, with the low at -$14.0 million in Q3 2023.
  • Average EBITDA over 5 years is -$2.5 million, with a median of -$8.2 million recorded in 2022.
  • Peak annual rise in EBITDA hit 577.57% in 2023, while the deepest fall reached 216.85% in 2023.
  • Over 5 years, EBITDA stood at $9.2 million in 2021, then tumbled by 173.17% to -$6.8 million in 2022, then soared by 577.57% to $32.2 million in 2023, then dropped by 4.56% to $30.8 million in 2024, then rose by 5.15% to $32.4 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at $32.4 million, -$13.1 million, and -$13.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.